Swedish Orphan Biovitrum Logo

Swedish Orphan Biovitrum

Develops innovative therapies for rare diseases in haematology, immunology, and specialty care.

SOBI | ST

Overview

Corporate Details

ISIN(s):
SE0000872095 (+51 more)
LEI:
549300124Y3MQI87PT35
Country:
Sweden
Address:
Tomtebodavagen 23A, 112 76 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Swedish Orphan Biovitrum (Sobi) is a global biopharmaceutical company dedicated to developing and delivering innovative therapies for people with rare and debilitating diseases. The company focuses its research, development, and commercialization efforts on treatments in the areas of haematology, immunology, and specialty care. Sobi leverages its expertise in protein biochemistry and biologics manufacturing to address significant unmet medical needs. The company is committed to improving patient lives by providing sustainable access to transformative treatments for rare disease communities worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-30 08:00
Declaration of Voting Results & Voting Rights Announcements
New number of shares and votes in Sobi
English 137.5 KB
2025-09-30 08:00
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Sobi
Swedish 126.9 KB
2025-08-29 08:00
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Sobi
Swedish 100.2 KB
2025-08-29 08:00
Declaration of Voting Results & Voting Rights Announcements
New number of shares and votes in Sobi
English 97.9 KB
2025-08-21 12:35
Share Issue/Capital Change
Sobi has completed issues of class C shares
English 151.8 KB
2025-08-21 12:35
Share Issue/Capital Change
Sobi har genomfört emissioner av C-aktier
Swedish 151.6 KB
2025-07-16 08:00
Quarterly Report
Swedish 4.1 MB
2025-07-16 08:00
Earnings Release
English 4.1 MB
2025-07-15 19:15
Share Issue/Capital Change
The Board of Directors of Sobi exercises authorisation for repurchase of shares…
English 138.4 KB
2025-07-15 19:15
Transaction in Own Shares
Sobis styrelse utnyttjar återköpsbemyndigande för säkerställande av bolagets åt…
Swedish 137.1 KB
2025-07-01 13:00
M&A Activity
Sobi uppdaterar avtalet med Apellis om royalty på Aspaveli® (systemisk pegcetac…
Swedish 193.0 KB
2025-07-01 13:00
M&A Activity
Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli…
English 202.6 KB
2025-06-28 00:55
Regulatory News Service
FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and…
English 227.3 KB
2025-06-28 00:55
Earnings Release
FDA godkänner Gamifant® (emapalumab-lzsg) som den första behandlingen för vuxna…
Swedish 244.4 KB
2025-05-08 11:30
Post-Annual General Meeting Information
Kommuniké från Sobis årsstämma
Swedish 148.7 KB

Automate Your Workflow. Get a real-time feed of all Swedish Orphan Biovitrum filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Swedish Orphan Biovitrum via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2020-11-23 Elisabeth Svanberg Other Buy 500 76,937.50 SEK
2020-08-28 Armin Reininger Other Other 4,563 870,428.90 SEK
2020-08-28 Armin Reininger Other Sell 4,563 870,428.90 SEK
2020-05-26 Guido Oelkers Other Other 164,223 34,979,499.00 SEK
2020-05-26 Armin Reininger Other Other 13,863 2,952,819.00 SEK
2020-05-26 Sofiane FAHMY Other Other 8,766 1,867,158.00 SEK
2020-05-15 Kristin Strandberg Other Other 86 16,933.40 SEK
2020-05-15 Katy Mazibuko Other Other 208 41,028.00 SEK
2020-05-15 Linda Therese Larsson Other Other 202 40,187.90 SEK

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.